Reports Q4 revenue $7.57M vs $9M last year. “I am incredibly proud of the progress we reported in the final quarter of this past fiscal year. Continued broad development of brepocitinib, positive data from our myasthenia gravis study, and expansion of IMVT-1402 into new indications underscore our commitment to patients. We remain focused on building value in our late-stage clinical pipeline, and on continued discipline on capital allocation across the portfolio,” said Matt Gline, CEO of Roivant. “We look forward to a number of exciting milestones later this year, including the upcoming brepocitinib readout in DM.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences: Strategic Leadership and Promising Developments Drive Buy Rating
- Is ROIV a Buy, Before Earnings?
- Strategic Leadership and Pipeline Advancements Drive Buy Rating for Roivant Sciences
- Strategic Advancements and Growth Potential Justify Buy Rating for Roivant Sciences
- Roivant Sciences Announces Leadership Changes at Immunovant